Beta Galactosidase Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Beta-galactosidase (GLB1) is a lysosomal hydrolase encoded by the GLB1 gene. It catalyzes the hydrolysis of terminal galactose residues from various glycoconjugates, including GM1 ganglioside and keratan sulfate. This enzyme is essential for normal lysosomal function and its deficiency causes GM1 gangliosidosis. [1]
| Property | Value | [2]
|----------|-------| [3]
| Protein Name | Beta-galactosidase | [4]
| Gene | GLB1 |
| UniProt ID | P16234 |
| PDB ID | 1JZ3 |
| Molecular Weight | 76 kDa (tetramer) |
| Subcellular Localization | Lysosome |
| Protein Family | Glycoside hydrolase family 35 |
Beta-galactosidase forms a homotetramer:
The enzyme catalyzes hydrolysis of:
In neurons, proper GM1 ganglioside turnover is essential for:
Accumulation of GM1 ganglioside in neurons causes:
[5] Suzuki Y, et al. (2001). Beta-galactosidase deficiency (GM1 gangliosidosis and Morquio B disease). Brain Development.
[1:1] Santamaria R, et al. (2007). Molecular basis of human beta-galactosidase deficiency. Human Mutation.
Beta-galactosidase activity serves as a biomarker for lysosomal function in neurodegenerative diseases. Reduced activity is observed in:
Beta-galactosidase activity is measured using fluorescent substrates (4-MUG) in:
Recombinant beta-galactosidase (轂-lambda) is being developed for:
AAV-mediated gene delivery approaches are in preclinical development for:
Pharmacological chaperones to enhance residual enzyme activity:
The study of Beta Galactosidase Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Walkley SU, et al. "Lysosomal storage diseases: Pathways and therapeutic strategies." Nat Rev Neurol. Nat Rev Neurol. 2023. ↩︎ ↩︎
Parenti G, et al. "Lysosomal storage diseases: From pathophysiology to therapy." Adv Pharmacol. Adv Pharmacol. 2023. ↩︎
Sun A. "Lysosomal storage disease overview." J Biochem. J Biochem. 2022. ↩︎
Wang RY, et al. "Enzyme replacement therapy for mucopolysaccharidoses." Mol Genet Metab. Mol Genet Metab. 2021. ↩︎
Platt FM, et al. "Lysosomal storage disorders." Nat Rev Dis Primers. Nat Rev Dis Primers. 2024. ↩︎